Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Hercules Capital reports Q2 NII 32c, consensus 32c » 16:19
07/29/21
07/29
16:19
07/29/21
16:19
HTGC

Hercules Capital

$17.40 /

+0.04 (+0.23%)

"During Q2 2021,…

"During Q2 2021, Hercules generated 100% coverage of our base dividend distribution with NII, delivered solid NAV accretion and maintained our strong liquidity position to fund our disciplined and controlled growth strategy," stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. "As a result, the Company was able to offset elevated repayment activities, deliver net debt portfolio growth of nearly $57 million and achieve the highest internal credit rating in our history. This strong operating performance extended the momentum from Q1, which led to record levels of new debt and equity commitments and total fundings of nearly $972 million and $634 million, respectively, for the first half of 2021." Bluestein added, "With the public and private equity markets performing exceptionally well, our technology and life sciences portfolio companies are benefitting from multiple ways to raise new capital or achieve liquidity events. Our equity and warrant portfolio has continued to march in parallel with the public markets, with 26 of our portfolio companies announcing or completing exit events year-to-date, of which 10 have completed initial public offerings. This has generated record undistributed earnings spillover of over $160 million, giving us additional flexibility to continue to invest in our team and platform for the long term while also delivering strong shareholder returns."

ShowHide Related Items >><<
HTGC Hercules Capital
$17.40 /

+0.04 (+0.23%)

HTGC Hercules Capital
$17.40 /

+0.04 (+0.23%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$17.40 /

+0.04 (+0.23%)

Tuesday
Hot Stocks
Hercules Capital declares Q2 supplemental cash dividend of 7c per share » 06:07
07/27/21
07/27
06:07
07/27/21
06:07
HTGC

Hercules Capital

$17.22 /

+0.08 (+0.47%)

Hercules Capital is…

Hercules Capital is pleased to announce that its Board of Directors has declared a supplemental cash distribution of 7c per share. This supplemental cash distribution will be paid out of Hercules Capital's undistributed taxable income as of June 30. The following shows the key dates of the supplemental distribution payment: Record Date August 11. Payment Date August 18.

ShowHide Related Items >><<
HTGC Hercules Capital
$17.22 /

+0.08 (+0.47%)

HTGC Hercules Capital
$17.22 /

+0.08 (+0.47%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$17.22 /

+0.08 (+0.47%)

Over a month ago
Hot Stocks
Nabriva Therapeutics agrees to extension of principal debt repayments » 07:55
06/03/21
06/03
07:55
06/03/21
07:55
NBRV

Nabriva Therapeutics

$1.39 /

+0.005 (+0.36%)

, HTGC

Hercules Capital

$17.19 /

-0.045 (-0.26%)

Nabriva Therapeutics plc…

Nabriva Therapeutics plc (NBRV) announced that it has reached an agreement with Hercules Capital, Inc. (HTGC) to extend principal payments under its existing loan agreement until at least January 1, 2022. Repayments of outstanding principal amounts under the company's debt facility with Hercules were scheduled to begin on July 1, 2021. Terms of the amended agreement provide for an initial six-month extension to January 1, 2022, with the ability to delay the principal debt repayments until July 1, 2022 upon achievement of certain financing and product revenue milestones.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$1.39 /

+0.005 (+0.36%)

HTGC Hercules Capital
$17.19 /

-0.045 (-0.26%)

NBRV Nabriva Therapeutics
$1.39 /

+0.005 (+0.36%)

03/12/21 Northland
Nabriva Therapeutics price target lowered to $6 from $9 at Northland
06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
HTGC Hercules Capital
$17.19 /

-0.045 (-0.26%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$17.19 /

-0.045 (-0.26%)

  • 11
    Dec
NBRV Nabriva Therapeutics
$1.39 /

+0.005 (+0.36%)

NBRV Nabriva Therapeutics
$1.39 /

+0.005 (+0.36%)

Hot Stocks
HiberCell announces $30M debt facility from Hercules Capital » 08:10
05/19/21
05/19
08:10
05/19/21
08:10
HTGC

Hercules Capital

$17.10 /

-0.085 (-0.49%)

HiberCell announced that…

HiberCell announced that it has completed a Series B financing round for gross proceeds of $67.4 million. Concurrent to this financing, HiberCell closed on a $30 million debt facility with Hercules Capital. The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors. Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate, also participated in the round. HiberCell will use the proceeds of the Series B financing and debt facility to support the clinical development of novel therapeutics targeting stress biology and innate immunity to address the role these play in prevention of cancer recurrence and metastasis.

ShowHide Related Items >><<
HTGC Hercules Capital
$17.10 /

-0.085 (-0.49%)

HTGC Hercules Capital
$17.10 /

-0.085 (-0.49%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$17.10 /

-0.085 (-0.49%)

Hot Stocks
Scynexis secures term loan facility for up to $60M » 08:49
05/14/21
05/14
08:49
05/14/21
08:49
SCYX

Scynexis

$6.80 /

-0.2 (-2.86%)

, HTGC

Hercules Capital

$16.63 /

+0.645 (+4.04%)

SCYNEXIS reported that it…

SCYNEXIS reported that it has secured a $60 million term loan facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank. The capital strengthens SCYNEXIS' balance sheet ahead of the anticipated commercial launch of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vaginal yeast infections, which is under regulatory review by the U.S. Food and Drug Administration with a PDUFA target action date of June 1, 2021. This non-dilutive financing further extends SCYNEXIS' projected cash runway into 2023, based on current operating plans. The $60M loan facility is available to SCYNEXIS in four tranches: SCYNEXIS receives the first tranche of $20M as part of the closing of the term loan facility; the second tranche of $10M will be triggered by FDA approval of ibrexafungerp for the treatment of vaginal yeast infections, and will be available through June 30, 2022; the third tranche of $5M will be triggered by the additional achievement of the primary endpoint in the CANDLE study, and will be available through June 30, 2022; and the remaining $25M in the fourth tranche will be available to SCYNEXIS from January 1, 2022 through December 31, 2023 in $5M increments, subject to certain terms and conditions, including in connection with net product revenues for ibrexafungerp over time. The term loan has a 30-month interest-only period from date of closing, extendable to 36 months upon FDA approval of ibrexafungerp for the treatment of vaginal yeast infections and up to 48 months upon achievement of certain conditions. The maturity date of the loan is on March 3, 2025, but would be automatically extended to May 1, 2025 upon the occurrence of certain conditions set forth in the loan documentation. Armentum Partners served as the company's financial advisor in connection with the loan facility.

ShowHide Related Items >><<
SCYX Scynexis
$6.80 /

-0.2 (-2.86%)

HTGC Hercules Capital
$16.63 /

+0.645 (+4.04%)

SCYX Scynexis
$6.80 /

-0.2 (-2.86%)

02/17/21 Maxim
Scynexis price target raised to $22 from $17 at Maxim
01/22/21 Guggenheim
Scynexis initiated with a Buy at Guggenheim
01/05/21 Cantor Fitzgerald
Scynexis initiated with an Overweight at Cantor Fitzgerald
12/28/20 H.C. Wainwright
Scynexis price target lowered to $20 from $35 at H.C. Wainwright
HTGC Hercules Capital
$16.63 /

+0.645 (+4.04%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
SCYX Scynexis
$6.80 /

-0.2 (-2.86%)

HTGC Hercules Capital
$16.63 /

+0.645 (+4.04%)

  • 17
    Dec
SCYX Scynexis
$6.80 /

-0.2 (-2.86%)

Conference/Events
Hercules Capital management to meet virtually with Piper Sandler » 04:55
05/13/21
05/13
04:55
05/13/21
04:55
HTGC

Hercules Capital

$15.99 /

-0.81 (-4.82%)

Virtual Meeting to be…

Virtual Meeting to be held on May 13 hosted by Piper Sandler.

ShowHide Related Items >><<
HTGC Hercules Capital
$15.99 /

-0.81 (-4.82%)

HTGC Hercules Capital
$15.99 /

-0.81 (-4.82%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$15.99 /

-0.81 (-4.82%)

Conference/Events
Hercules Capital management to meet virtually with Piper Sandler » 11:14
05/12/21
05/12
11:14
05/12/21
11:14
HTGC

Hercules Capital

$16.59 /

-0.21 (-1.25%)

Virtual Meeting to be…

Virtual Meeting to be held on May 13 hosted by Piper Sandler.

ShowHide Related Items >><<
HTGC Hercules Capital
$16.59 /

-0.21 (-1.25%)

HTGC Hercules Capital
$16.59 /

-0.21 (-1.25%)

04/30/21 B. Riley
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley
04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
HTGC Hercules Capital
$16.59 /

-0.21 (-1.25%)

Over a quarter ago
Recommendations
Hercules Capital price target raised to $18.50 from $16.50 at B. Riley » 07:41
04/30/21
04/30
07:41
04/30/21
07:41
HTGC

Hercules Capital

$17.54 /

+0.23 (+1.33%)

B. Riley analyst Sarkis…

B. Riley analyst Sarkis Sherbetchyan raised the firm's price target on Hercules Capital to $18.50 from $16.50 and reiterates a Buy rating on the shares following the Q1 beat.

ShowHide Related Items >><<
HTGC Hercules Capital
$17.54 /

+0.23 (+1.33%)

HTGC Hercules Capital
$17.54 /

+0.23 (+1.33%)

04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
11/24/20 B. Riley
Hercules Capital price target raised to $14.50 from $12.50 at B. Riley
HTGC Hercules Capital
$17.54 /

+0.23 (+1.33%)

Earnings
Hercules Capital reports Q1 NII 30c, consensus 30c » 16:12
04/29/21
04/29
16:12
04/29/21
16:12
HTGC

Hercules Capital

$17.57 /

+0.26 (+1.50%)

"We are off to a…

"We are off to a terrific start to 2021 with record levels of new commitments and fundings for the first quarter," stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. "Notably, we closed nearly $531 million in new debt and equity commitments, while improving and maintaining strong credit quality with the highest internal credit rating on our debt investment portfolio in 10 years."

ShowHide Related Items >><<
HTGC Hercules Capital
$17.57 /

+0.26 (+1.50%)

HTGC Hercules Capital
$17.57 /

+0.26 (+1.50%)

04/27/21 Oppenheimer
Hercules Capital initiated with an Outperform at Oppenheimer
03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
11/24/20 B. Riley
Hercules Capital price target raised to $14.50 from $12.50 at B. Riley
HTGC Hercules Capital
$17.57 /

+0.26 (+1.50%)

Initiation
Hercules Capital initiated with an Outperform at Oppenheimer » 16:10
04/27/21
04/27
16:10
04/27/21
16:10
HTGC

Hercules Capital

$17.33 /

+0.26 (+1.52%)

Oppenheimer analyst…

Oppenheimer analyst Mitchel Penn initiated coverage of Hercules Capital with an Outperform rating and $17.50 price target. The analyst projects that Hercules can earn a 14.80% return on equity, and given an estimated cost of equity capital of 9.5%, he calculates a fair value of $17.50 per share. Hercules is likely to benefit from a "strong" initial public offering and special purpose acquisition company market for another year or two in the form of net realized/unrealized gains on its equity and warrant portfolio, Penn tells investors in a research note.

ShowHide Related Items >><<
HTGC Hercules Capital
$17.33 /

+0.26 (+1.52%)

HTGC Hercules Capital
$17.33 /

+0.26 (+1.52%)

03/25/21 RBC Capital
Hercules Capital initiated with an Outperform at RBC Capital
01/08/21 Piper Sandler
Hercules Capital price target raised to $16 from $13 at Piper Sandler
11/24/20 B. Riley
Hercules Capital price target raised to $14.50 from $12.50 at B. Riley
11/19/20 JMP Securities
TriplePoint Venture resumed with an Outperform at JMP Securities
HTGC Hercules Capital
$17.33 /

+0.26 (+1.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.